Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy-Reference-Cited by-同舟云学术

Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy

Published:2021-05-28 Issue:11 Volume:64 Page:7507-7532
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Wang Zhisong¹²,Gao Yan¹³,He Lei¹,Sun Shuhao¹,Xia Tingting¹,Hu Lu¹,Yao Licheng¹,Wang Liangliang¹,Li Dan¹,Shi Hui¹²,Liao Xuebin¹²^ORCID

Affiliation:

1. School of Pharmaceutical Sciences, Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education), Beijing Advanced Innovation Center for Human Brain Protection, Tsinghua University, Beijing 100084, China

2. Joint Graduate Program of Peking-Tsinghua-NIBS, School of Life Sciences, Tsinghua University, Beijing 100084, China

3. Central Laboratory, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China

Funder

Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases

Roche Postdoctoral Fellowship Program

1000 Talents Recruitment Program

Tsinghua-Peking Centre for Life Sciences

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c00179

Reference58 articles.

1. Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

2. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

3. Trends in the global immuno-oncology landscape

4. Cancer immunotherapy comes of age

5. Cancer immunotherapy using checkpoint blockade

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads;European Journal of Medicinal Chemistry;2024-10

2. Small molecule innate immune modulators in cancer therapy;Frontiers in Immunology;2024-09-10

3. Design and Optimization of Selectivity-Tunable Toll-like Receptor 7/8 Agonists as Novel Antibody–Drug Conjugate Payloads;Journal of Medicinal Chemistry;2024-08-22

4. Design, Synthesis, and Biological Evaluation of New 2,6,7-Substituted Purine Derivatives as Toll-like Receptor 7 Agonists for Intranasal Vaccine Adjuvants;Journal of Medicinal Chemistry;2024-05-24

5. Targeting tumor‑associated macrophages: Critical players in tumor progression and therapeutic strategies (Review);International Journal of Oncology;2024-04-30